Today, New Jersey’s Senate Health, Human Services and Senior Citizens Committee unanimously approved legislation to add sickle cell anemia as a qualifying condition for the state’s medical marijuana program.
The measure, Assembly Bill 913/Senate Bill 2392, has already cleared the full Assembly and is now moving through the Senate after today’s committee approval. The proposal would expressly allow patients with sickle cell anemia—a chronic and frequently debilitating blood disorder that affects Black Americans at disproportionately high rates—to access medical marijuana. If passed by the Senate, it will be sent to outgoing Governor Phil Murphy.
Supporters of the bill say it would offer patients a vital alternative for managing severe and persistent pain associated with the condition.
New Jersey’s medical marijuana law, adopted in 2010, currently covers conditions such as chronic pain, cancer, multiple sclerosis, and PTSD. Even with the state’s recreational marijuana market now open, medical patients continue to receive key benefits, including exemption from the standard cannabis sales tax, higher purchase and possession limits, and often lower prices with wider product availability.
If enacted, A913 would formally include sickle cell anemia within the state’s list of qualifying conditions, ensuring that patients coping with its intense symptoms have full access to New Jersey’s medical marijuana program.
More articles from The Marijuana Herald can be found below.
